ARM A : IV iron + epoietin zeta + ARM B: IV iron + epoietin zeta sequence + ARM C : single epoietin zeta
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Solid Cancer Metastatic Disease
Conditions
Solid Cancer Metastatic Disease, Lymphoid Disease
Trial Timeline
Apr 1, 2013 → Nov 1, 2014
NCT ID
NCT02213653About ARM A : IV iron + epoietin zeta + ARM B: IV iron + epoietin zeta sequence + ARM C : single epoietin zeta
ARM A : IV iron + epoietin zeta + ARM B: IV iron + epoietin zeta sequence + ARM C : single epoietin zeta is a approved stage product being developed by Roche for Solid Cancer Metastatic Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT02213653. Target conditions include Solid Cancer Metastatic Disease, Lymphoid Disease.
What happened to similar drugs?
4 of 12 similar drugs in Solid Cancer Metastatic Disease were approved
Approved (4) Terminated (1) Active (8)
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02213653 | Approved | Terminated |
Competing Products
20 competing products in Solid Cancer Metastatic Disease